CA2318263A1 - Method for treating inflammatory diseases using heat shock proteins - Google Patents

Method for treating inflammatory diseases using heat shock proteins Download PDF

Info

Publication number
CA2318263A1
CA2318263A1 CA002318263A CA2318263A CA2318263A1 CA 2318263 A1 CA2318263 A1 CA 2318263A1 CA 002318263 A CA002318263 A CA 002318263A CA 2318263 A CA2318263 A CA 2318263A CA 2318263 A1 CA2318263 A1 CA 2318263A1
Authority
CA
Canada
Prior art keywords
heat shock
shock protein
mammal
disease
hsp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002318263A
Other languages
English (en)
French (fr)
Inventor
Angela Francisca Haczku
Erwin W. Gelfand
Katalin Veronika Lukacs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Jewish Health
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2318263A1 publication Critical patent/CA2318263A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002318263A 1998-01-23 1999-01-22 Method for treating inflammatory diseases using heat shock proteins Abandoned CA2318263A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1233098A 1998-01-23 1998-01-23
US09/012,330 1998-01-23
PCT/US1999/001421 WO1999037319A1 (en) 1998-01-23 1999-01-22 Method for treating inflammatory diseases using heat shock proteins

Publications (1)

Publication Number Publication Date
CA2318263A1 true CA2318263A1 (en) 1999-07-29

Family

ID=21754459

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002318263A Abandoned CA2318263A1 (en) 1998-01-23 1999-01-22 Method for treating inflammatory diseases using heat shock proteins

Country Status (16)

Country Link
US (2) US20020006410A1 (enExample)
EP (1) EP1049483A1 (enExample)
JP (1) JP2002509074A (enExample)
KR (1) KR20010040389A (enExample)
CN (1) CN1324243A (enExample)
AU (1) AU2337499A (enExample)
BR (1) BR9907228A (enExample)
CA (1) CA2318263A1 (enExample)
CZ (1) CZ20002669A3 (enExample)
HU (1) HUP0100241A2 (enExample)
IL (1) IL137404A0 (enExample)
NO (1) NO20003775L (enExample)
PL (1) PL342166A1 (enExample)
TR (1) TR200002973T2 (enExample)
WO (1) WO1999037319A1 (enExample)
ZA (1) ZA99499B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
WO2000048622A2 (en) * 1999-02-22 2000-08-24 University Of Iowa Research Foundation Method for inhibiting inflammatory responses
WO2001022816A1 (en) * 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
CA2460396A1 (en) * 2001-10-01 2003-04-10 Duke University Isolated grp94 ligand binding domain polypeptide and nucleic acid encoding same, crystalline form of same, and screening methods employing same
AU2003216288B2 (en) * 2002-02-13 2009-09-24 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
KR100615389B1 (ko) * 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
US20100111927A1 (en) * 2002-08-23 2010-05-06 Sunyoung Kim Compositions Comprising Actinidia and Methods of Use Thereof
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
EP1951282A4 (en) * 2005-10-20 2009-09-02 Cbio Ltd TREATMENT OF HYPERSENSITIVITY
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
PL2659904T3 (pl) 2008-06-26 2016-01-29 Orphazyme Aps Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
EP2391229B1 (en) 2009-01-29 2015-07-15 Alfa Biogene International B.V. Functional food product comprising heat shock protein or a hydrolysate thereof from alfalfa
EP2397074B1 (en) 2010-06-19 2012-10-24 M Stenqvist AB A system and computer readable medium for determination of transpulmonary pressure in a patient connected to a breathing apparatus
DK2646044T3 (da) 2010-11-30 2019-11-25 Orphazyme As Metoder til at øge den intracellulære aktivitet af Hsp70
WO2012097255A2 (en) * 2011-01-14 2012-07-19 Scott & White Healthcare Therapeutic effect of heat shock proteins in preventing amylin aggregation in type 2 diabetes mellitus
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2012174549A2 (en) * 2011-06-16 2012-12-20 Children's Hospital Medical Center Blockade of eosinophil production by toll-like receptors
US10034915B2 (en) 2011-06-23 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
JP2015504919A (ja) 2012-01-25 2015-02-16 プロテオステイシス セラピューティクス，インコーポレイテッド プロテアソーム活性を調節する化合物
KR20250069686A (ko) 2014-09-15 2025-05-19 제브라 덴마크 에이/에스 아리모클로몰 제제
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
LT3448382T (lt) 2016-04-29 2021-04-12 Orphazyme A/S Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
CN106220718B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP60及其应用
CN106243203B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP70及其应用
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
BR122023023216A2 (pt) 2018-06-27 2024-02-20 Proteostasis Therapeutics, Inc. Compostos, composição farmacêutica e uso de uma quantidade eficaz de um composto
CN112585130A (zh) 2018-06-27 2021-03-30 蛋白质平衡治疗股份有限公司 蛋白酶体活性增强化合物
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
US20230416224A1 (en) 2020-11-19 2023-12-28 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
CN114046596B (zh) * 2021-11-17 2022-09-23 重庆大学 基于trp生化指标检测的室内空气质量控制系统及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
DE69126668T2 (de) * 1990-11-08 1997-10-23 University College London, London Mycobacterium als adjuvans für antigene
GB9211736D0 (en) * 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
EP0941315B1 (en) * 1996-11-26 2006-03-01 Stressgen Biotechnologies Corporation Fusion proteins containing stress proteins for inducing immune responses

Also Published As

Publication number Publication date
CN1324243A (zh) 2001-11-28
EP1049483A1 (en) 2000-11-08
HUP0100241A2 (hu) 2001-06-28
PL342166A1 (en) 2001-05-21
CZ20002669A3 (cs) 2001-11-14
US20070179087A1 (en) 2007-08-02
IL137404A0 (en) 2001-07-24
JP2002509074A (ja) 2002-03-26
ZA99499B (en) 1999-07-22
AU2337499A (en) 1999-08-09
BR9907228A (pt) 2000-10-24
TR200002973T2 (tr) 2001-02-21
WO1999037319A1 (en) 1999-07-29
US20020006410A1 (en) 2002-01-17
NO20003775L (no) 2000-09-22
KR20010040389A (ko) 2001-05-15
NO20003775D0 (no) 2000-07-21

Similar Documents

Publication Publication Date Title
US20020006410A1 (en) Method for treating inflammatory diseases using heat shock proteins
Moller et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis.
Borish et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma
US5908620A (en) Treatment for diseases involving inflammation
Smaldone Repurposing of gamma interferon via inhalation delivery
Miyahara et al. IL-13 is essential to the late-phase response in allergic rhinitis
US20230338396A1 (en) Cannabidiol as a therapeutic modality for covid-19
US20240076393A1 (en) Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
JP2013545751A (ja) 修飾された免疫調節粒子
US6248723B1 (en) Method for treatment of inflammatory disease
US20070065367A1 (en) Method of treating pulmonary disease with interferons
Li et al. Therapeutic effects of DNA vaccine on allergen-induced allergic airway inflammation in mouse model
Park et al. Therapeutic anti-psoriatic effects of myeloid-derived suppressor cells in combination with systemic tacrolimus (FK-506) in an imiquimod-induced mouse model of psoriasis
US20190175502A1 (en) Methods and compositions for treating lung disease of prematurity
US20020141995A1 (en) Method for treatment of inflammatory disease
US20230000818A1 (en) Cannabichromene as a therapeutic modality for covid-19
US7067480B2 (en) Compositions and methods of use for anti-inflammatory agents
MXPA00007148A (es) Metodo para el tratamiento de enfermedades inflamatorias usando proteinas de choque termico
JP5175198B2 (ja) インターフェロンを用いる肺疾患の処置方法
KR20100123240A (ko) 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
US20120183499A1 (en) Method of treating pulmonary disease with interferons
WO2025231092A1 (en) Compositions and methods for the stimulation of intermediate macrophages and treatments therewith
WO2022005321A1 (en) Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
EP0756871A1 (en) Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
EP1265634A1 (en) Method and composition for treating airway hyperresponsiveness

Legal Events

Date Code Title Description
FZDE Discontinued